The Lancet Public Health, July 2023, Volume 8, Issue 7, Pages e473-e574
Read the current issue of The Lancet Public Health, a monthly open access journal contributing to advancing public health practice and policy making worldwide
Related Articles
Impact of Patient Access to Care on Rates of Febrile Neutropenia Post Inpatient Administration of a Colony-Stimulating Factor
This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.
AMA protests changes to key vaccine advisory committee
The organisation, which represents more than 270 000 physicians and medical students, has been reluctant to criticise the Trump administration’s actions, until now. Susan Jaffe reports.
Genomics | bioRxiv
bioRxiv – the preprint server for biology, operated by Cold Spring Harbor Laboratory, a research and educational institution
Sodium–glucose co-transporter inhibitors—who would have guessed?
“Prediction is very difficult, especially about the future”; whether it is the Nobel laureate Niels Bohr or others who have spoken on this matter, this…
More options for young children with type 1 diabetes
Hybrid closed-loop insulin delivery systems are transforming the management of type 1 diabetes. Young children with type 1 diabetes are arguably the most challenging age…
Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial
Sotagliflozin reduced MACE, with independent reductions in myocardial infarction and stroke, among patients with type 2 diabetes, chronic kidney disease, and additional cardiovascular risk. The…
Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial
Efsitora showed non-inferior HbA1c reductions and similar rates of combined clinically significant or severe hypoglycaemia versus glargine U100 in participants with type 2 diabetes treated…
Efficacy and safety of automated insulin delivery in children aged 2–6 years (LENNY): an open-label, multicentre, randomised, crossover trial
In children aged 2–6 years with type 1 diabetes, the TIR with the MiniMed 780G system in auto mode was non-inferior to that in manual+SBL…
Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial
Efsitora showed non-inferior HbA1c reductions and similar rates of combined clinically significant or severe hypoglycaemia versus glargine U100 in participants with type 2 diabetes treated…